|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
increases expression |
EXP |
procymidone results in increased expression of ABCB11 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
increases expression |
ISO |
procymidone results in increased expression of ABCB4 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
EXP |
procymidone results in increased expression of ABCC2 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Acly |
ATP citrate lyase |
decreases expression multiple interactions increases expression |
EXP |
procymidone results in decreased expression of ACLY mRNA [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of ACLY mRNA procymidone results in increased expression of ACLY mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr11:100,367,178...100,418,826
Ensembl chr11:100,367,179...100,418,826
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
decreases expression multiple interactions increases expression |
EXP |
procymidone results in decreased expression of ACOT1 mRNA [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of ACOT1 mRNA procymidone results in increased expression of ACOT1 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of ACOX1 mRNA procymidone results in decreased expression of ACOX1 mRNA procymidone results in increased expression of ACOX1 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ACTN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr12:80,214,316...80,307,165
Ensembl chr12:80,214,321...80,307,145
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
increases expression |
ISO |
procymidone results in increased expression of ADH4 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 3:138,121,217...138,138,444
Ensembl chr 3:138,121,227...138,136,653
|
|
G |
Ak3 |
adenylate kinase 3 |
increases expression |
ISO |
procymidone results in increased expression of AK3 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr19:28,968,715...29,026,122
Ensembl chr19:28,998,233...29,025,361
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions |
ISO |
[Diethylhexyl Phthalate co-treated with procymidone] results in decreased expression of AMH mRNA |
CTD |
PMID:34051340 |
|
NCBI chr10:80,641,074...80,643,513
Ensembl chr10:80,641,077...80,643,482
|
|
G |
Ang4 |
angiogenin, ribonuclease A family, member 4 |
affects expression |
EXP |
procymidone affects the expression of ANG4 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr14:52,001,349...52,011,047
Ensembl chr14:52,001,335...52,011,047
|
|
G |
Angpt4 |
angiopoietin 4 |
increases expression multiple interactions |
EXP |
procymidone results in increased expression of ANGPT4 mRNA [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of ANGPT4 mRNA |
CTD |
PMID:33246813 |
|
NCBI chr 2:151,753,127...151,787,257
Ensembl chr 2:151,753,130...151,787,257
|
|
G |
Ano1 |
anoctamin 1, calcium activated chloride channel |
affects expression |
EXP |
procymidone affects the expression of ANO1 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 7:144,142,286...144,305,762
Ensembl chr 7:144,142,286...144,305,711
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
increases expression |
ISO |
procymidone results in increased expression of APEX1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases activity affects binding increases expression decreases expression |
ISO EXP |
procymidone binds to and results in decreased activity of AR protein procymidone results in decreased activity of AR protein procymidone binds to AR protein procymidone results in increased expression of AR mRNA [procymidone co-treated with prochloraz co-treated with vinclozolin] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; [procymidone co-treated with vinclozolin] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; Dihydrotestosterone inhibits the reaction [procymidone results in increased activity of AR protein]; procymidone inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; procymidone inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; procymidone inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; procymidone inhibits the reaction [Metribolone binds to and results in increased activity of AR protein]; procymidone inhibits the reaction [Metribolone binds to AR protein]; procymidone inhibits the reaction [Metribolone results in increased activity of AR protein] procymidone results in decreased expression of AR mRNA |
CTD |
PMID:10053169 PMID:10188193 PMID:14565775 PMID:15064155 PMID:15589981 PMID:15686871 PMID:18315717 PMID:18324785 PMID:20821581 PMID:21310686 PMID:26602169 PMID:33049310 PMID:35913088 More...
|
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Asic3 |
acid-sensing ion channel 3 |
decreases expression |
ISO |
procymidone results in decreased expression of ASIC3 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:24,618,449...24,622,836
Ensembl chr 5:24,618,390...24,622,833
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
EXP |
procymidone results in increased expression of ATF4 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
EXP |
procymidone results in increased expression of ATF6 mRNA; procymidone results in increased expression of ATF6 protein |
CTD |
PMID:35913088 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
decreases expression |
ISO |
procymidone results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
EXP |
procymidone results in decreased expression of ATP5B mRNA |
CTD |
PMID:35913088 |
|
NCBI chr10:127,919,176...127,926,257
Ensembl chr10:127,919,142...127,926,260
|
|
G |
Bace1 |
beta-site APP cleaving enzyme 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BACE1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:45,749,878...45,775,694
Ensembl chr 9:45,749,878...45,775,697
|
|
G |
Bace2 |
beta-site APP-cleaving enzyme 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BACE2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:97,157,928...97,244,136
Ensembl chr16:97,157,942...97,244,136
|
|
G |
Bax |
BCL2-associated X protein |
increases expression |
ISO EXP |
procymidone results in increased expression of BAX mRNA |
CTD |
PMID:15686871 PMID:33413771 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
decreases expression |
ISO |
procymidone results in decreased expression of BCKDK mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 7:127,503,245...127,508,836
Ensembl chr 7:127,503,254...127,509,393
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BDNF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bsn |
bassoon |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BSN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:107,973,221...108,067,618
Ensembl chr 9:107,973,221...108,067,583
|
|
G |
C3 |
complement component 3 |
increases expression multiple interactions |
ISO |
procymidone results in increased expression of C3 mRNA [vinclozolin co-treated with procymidone co-treated with Flutamide] results in increased expression of C3 mRNA |
CTD |
PMID:17420220 |
|
NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136
|
|
G |
Cacna1a |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1A mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:85,065,257...85,366,880
Ensembl chr 8:85,065,268...85,366,875
|
|
G |
Cacna1b |
calcium channel, voltage-dependent, N type, alpha 1B subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:24,493,872...24,653,210
Ensembl chr 2:24,493,899...24,653,164
|
|
G |
Cacna1c |
calcium channel, voltage-dependent, L type, alpha 1C subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:118,564,201...119,174,345
Ensembl chr 6:118,564,201...119,173,851
|
|
G |
Cacna1d |
calcium channel, voltage-dependent, L type, alpha 1D subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1D mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:29,761,898...30,213,113
Ensembl chr14:29,761,896...30,213,412
|
|
G |
Cacna1g |
calcium channel, voltage-dependent, T type, alpha 1G subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1G mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:94,299,217...94,365,226
Ensembl chr11:94,299,217...94,365,024
|
|
G |
Cacna1i |
calcium channel, voltage-dependent, alpha 1I subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNA1I mRNA |
CTD |
PMID:25607892 |
|
NCBI chr15:80,171,439...80,282,493
Ensembl chr15:80,171,439...80,282,480
|
|
G |
Cacna2d3 |
calcium channel, voltage-dependent, alpha2/delta subunit 3 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:28,626,900...29,444,732
Ensembl chr14:28,626,900...29,443,821
|
|
G |
Cacnb1 |
calcium channel, voltage-dependent, beta 1 subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:97,892,339...97,913,860
Ensembl chr11:97,892,334...97,913,860
|
|
G |
Cacnb3 |
calcium channel, voltage-dependent, beta 3 subunit |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr15:98,526,317...98,542,410
Ensembl chr15:98,528,721...98,542,410
|
|
G |
Cacng2 |
calcium channel, voltage-dependent, gamma subunit 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr15:77,876,119...78,004,420
Ensembl chr15:77,875,948...78,004,228
|
|
G |
Cacng6 |
calcium channel, voltage-dependent, gamma subunit 6 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:3,472,017...3,484,183
Ensembl chr 7:3,472,711...3,484,183
|
|
G |
Cacng7 |
calcium channel, voltage-dependent, gamma subunit 7 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNG7 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:3,381,341...3,416,737
Ensembl chr 7:3,381,471...3,416,737
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CADM1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:47,441,468...47,773,578
Ensembl chr 9:47,441,471...47,769,413
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
procymidone results in decreased expression of CALR mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II, beta |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:5,919,642...6,016,401
Ensembl chr11:5,919,644...6,016,362
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CAMK2G mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:20,784,943...20,844,225
Ensembl chr14:20,784,943...20,844,156
|
|
G |
Casp12 |
caspase 12 |
increases expression |
EXP |
procymidone results in increased expression of CASP12; procymidone results in increased expression of CASP12 mRNA |
CTD |
PMID:33413771 PMID:35913088 |
|
NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP |
procymidone results in increased expression of CASP3; procymidone results in increased expression of CASP3 mRNA |
CTD |
PMID:33413771 PMID:35913088 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
increases expression |
EXP |
procymidone results in increased expression of CASP9; procymidone results in increased expression of CASP9 mRNA |
CTD |
PMID:33413771 PMID:35913088 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
procymidone results in decreased expression of CCND1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
procymidone results in increased expression of CCNE1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Cd44 |
CD44 antigen |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CD44 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cd81 |
CD81 antigen |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CD81 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:142,606,487...142,621,667
Ensembl chr 7:142,606,476...142,621,671
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in decreased expression of CDH1 protein |
CTD |
PMID:34503147 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
decreases expression multiple interactions increases expression affects expression |
EXP |
procymidone results in decreased expression of CFTR protein [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of CFTR protein; [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of CFTR mRNA procymidone results in increased expression of CFTR mRNA procymidone affects the expression of CFTR mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Chga |
chromogranin A |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CHGA mRNA |
CTD |
PMID:25607892 |
|
NCBI chr12:102,521,200...102,531,286
Ensembl chr12:102,521,228...102,531,287
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
EXP |
procymidone results in decreased expression of CLDN1 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591
|
|
G |
Clu |
clusterin |
increases expression multiple interactions |
ISO |
procymidone results in increased expression of CLU mRNA [vinclozolin co-treated with procymidone] results in increased expression of CLU mRNA |
CTD |
PMID:12563111 PMID:15590119 |
|
NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996
|
|
G |
Cpd |
carboxypeptidase D |
increases expression |
ISO |
procymidone results in increased expression of CPD mRNA |
CTD |
PMID:15686871 |
|
NCBI chr11:76,668,034...76,737,834
Ensembl chr11:76,669,250...76,737,844
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of CPT1A mRNA procymidone results in decreased expression of CPT1A mRNA procymidone results in increased expression of CPT1A mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
decreases expression |
ISO |
procymidone results in decreased expression of CRHR2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 6:55,067,033...55,110,001
Ensembl chr 6:55,067,034...55,110,001
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases expression |
ISO |
procymidone results in decreased expression of CXCL10 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
decreases expression |
ISO |
procymidone results in decreased expression of CXCL2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression decreases expression |
ISO EXP |
procymidone results in increased expression of CYP11A1 mRNA procymidone results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:15686871 PMID:35913088 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
affects expression |
EXP |
procymidone affects the expression of CYP27A1 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases expression |
EXP |
procymidone results in increased expression of and results in increased activity of CYP2E1 protein procymidone results in increased expression of CYP2E1 mRNA |
CTD |
PMID:12787915 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
affects expression |
EXP |
procymidone affects the expression of CYP7A1 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Dad1 |
defender against cell death 1 |
decreases expression |
ISO |
procymidone results in decreased expression of DAD1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr14:54,472,942...54,491,386
Ensembl chr14:54,472,936...54,491,561
|
|
G |
Dbh |
dopamine beta hydroxylase |
increases expression |
ISO |
procymidone results in increased expression of DBH mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 2:27,055,519...27,073,216
Ensembl chr 2:27,055,245...27,073,212
|
|
G |
Dbi |
diazepam binding inhibitor |
decreases expression |
ISO |
procymidone results in decreased expression of DBI mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 1:120,041,010...120,048,826
Ensembl chr 1:120,041,010...120,048,808
|
|
G |
Dcc |
deleted in colorectal carcinoma |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DCC mRNA |
CTD |
PMID:25607892 |
|
NCBI chr18:71,386,703...72,484,299
Ensembl chr18:71,386,705...72,484,140
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
procymidone results in increased expression of DDIT3 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Defa20 |
defensin, alpha, 20 |
increases expression multiple interactions affects expression |
EXP |
procymidone results in increased expression of DEFA20 mRNA [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of DEFA20 mRNA procymidone affects the expression of DEFA20 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 8:21,999,274...22,000,253
Ensembl chr 8:21,999,274...22,000,253
|
|
G |
Defa21 |
defensin, alpha, 21 |
multiple interactions affects expression |
EXP |
[tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of DEFA5 mRNA procymidone affects the expression of DEFA5 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 8:21,515,561...21,516,533
Ensembl chr 8:21,515,561...21,516,532
|
|
G |
Defa3 |
defensin, alpha, 3 |
increases expression multiple interactions affects expression |
EXP |
procymidone results in increased expression of DEFA3 mRNA [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of DEFA3 mRNA procymidone affects the expression of DEFA3 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 8:21,777,425...21,778,393
Ensembl chr 8:21,777,425...21,778,393
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of DGAT1 mRNA procymidone results in decreased expression of DGAT1 mRNA procymidone results in increased expression of DGAT1 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of DGAT2 mRNA procymidone results in decreased expression of DGAT2 mRNA procymidone results in increased expression of DGAT2 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DLG1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:31,482,261...31,692,174
Ensembl chr16:31,482,261...31,693,947
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of DLG4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLG4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:69,908,029...69,938,107
Ensembl chr11:69,907,768...69,938,348
|
|
G |
Dlgap3 |
DLG associated protein 3 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:127,062,090...127,130,815
Ensembl chr 4:127,062,997...127,130,815
|
|
G |
Dlgap4 |
DLG associated protein 4 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:156,455,431...156,606,283
Ensembl chr 2:156,455,625...156,606,283
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression |
ISO |
procymidone results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 4:40,722,468...40,734,965
Ensembl chr 4:40,722,150...40,737,149
|
|
G |
Doc2a |
double C2, alpha |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DOC2A mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:126,446,525...126,451,877
Ensembl chr 7:126,446,588...126,451,877
|
|
G |
Dpp10 |
dipeptidylpeptidase 10 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPP10 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:123,259,871...124,773,774
Ensembl chr 1:123,249,200...124,773,776
|
|
G |
Dpp6 |
dipeptidylpeptidase 6 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DPP6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 5:27,022,355...27,932,498
Ensembl chr 5:27,022,201...27,932,503
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPYD mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573
|
|
G |
Drd1 |
dopamine receptor D1 |
increases expression |
ISO |
procymidone results in increased expression of DRD1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
EXP |
procymidone results in increased expression of EIF2AK3 mRNA; procymidone results in increased expression of EIF2AK3 protein |
CTD |
PMID:35913088 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases expression |
EXP |
procymidone results in increased expression of EIF2S1 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
increases expression |
EXP |
procymidone results in increased expression of ERN1 mRNA; procymidone results in increased expression of ERN1 protein |
CTD |
PMID:35913088 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
procymidone binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
procymidone binds to and results in increased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fabp1 |
fatty acid binding protein 1, liver |
decreases expression multiple interactions increases expression |
EXP |
procymidone results in decreased expression of FABP1 mRNA [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of FABP1 mRNA procymidone results in increased expression of FABP1 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
affects expression |
EXP |
procymidone affects the expression of FABP6 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr11:43,486,867...43,492,389
Ensembl chr11:43,486,876...43,492,367
|
|
G |
Fasn |
fatty acid synthase |
decreases expression multiple interactions increases expression |
EXP |
procymidone results in decreased expression of FASN mRNA [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of FASN mRNA procymidone results in increased expression of FASN mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fgf15 |
fibroblast growth factor 15 |
affects expression |
EXP |
procymidone affects the expression of FGF15 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr X:67,722,144...67,761,569
Ensembl chr X:67,722,147...67,761,569
|
|
G |
Fshb |
follicle stimulating hormone beta |
increases expression multiple interactions |
ISO |
procymidone results in increased expression of FSHB protein [vinclozolin co-treated with procymidone] results in increased expression of FSHB protein |
CTD |
PMID:12563111 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Fyn |
Fyn proto-oncogene |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FYN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:39,245,735...39,441,377
Ensembl chr10:39,244,851...39,441,377
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRA4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 5:71,727,077...71,815,651
Ensembl chr 5:71,727,092...71,815,651
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRB1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 5:71,815,264...72,306,915
Ensembl chr 5:71,815,456...72,306,380
|
|
G |
Gck |
glucokinase |
multiple interactions decreases expression affects expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of GCK mRNA procymidone results in decreased expression of GCK mRNA procymidone affects the expression of GCK mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gdnf |
glial cell line derived neurotrophic factor |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GDNF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GLS mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391
|
|
G |
Gng5 |
G protein subunit gamma 5 |
decreases expression |
ISO |
procymidone results in decreased expression of GNG5 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 3:146,205,591...146,211,298
Ensembl chr 3:146,205,562...146,211,327
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
decreases expression |
ISO |
procymidone results in decreased expression of GNRH1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr14:67,982,717...67,986,889
Ensembl chr14:67,982,630...67,986,888
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of GPAM mRNA procymidone results in decreased expression of GPAM mRNA procymidone results in increased expression of GPAM mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr19:55,056,067...55,115,666
Ensembl chr19:55,055,700...55,115,670
|
|
G |
Gria2 |
glutamate receptor, ionotropic, AMPA2 (alpha 2) |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:80,588,757...80,711,534
Ensembl chr 3:80,588,757...80,710,142
|
|
G |
Gria4 |
glutamate receptor, ionotropic, AMPA4 (alpha 4) |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:4,417,893...4,796,250
Ensembl chr 9:4,417,896...4,796,234
|
|
G |
Grik1 |
glutamate receptor, ionotropic, kainate 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIK1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:87,692,789...88,087,751
Ensembl chr16:87,692,788...88,087,153
|
|
G |
Grik2 |
glutamate receptor, ionotropic, kainate 2 (beta 2) |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:48,969,776...49,666,523
Ensembl chr10:48,970,929...49,664,862
|
|
G |
Grin1 |
glutamate receptor, ionotropic, NMDA1 (zeta 1) |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:25,181,189...25,209,199
Ensembl chr 2:25,181,193...25,209,199
|
|
G |
Grin2b |
glutamate receptor, ionotropic, NMDA2B (epsilon 2) |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN2B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:135,690,219...136,150,658
Ensembl chr 6:135,690,231...136,150,509
|
|
G |
Grip1 |
glutamate receptor interacting protein 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIP1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:119,289,810...119,923,172
Ensembl chr10:119,289,735...119,923,166
|
|
G |
Gzmd |
granzyme D |
decreases expression |
EXP |
procymidone results in decreased expression of GZMD mRNA |
CTD |
PMID:36764477 |
|
NCBI chr14:56,367,013...56,370,060
Ensembl chr14:56,367,013...56,370,065
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[fludioxonil co-treated with cyprodinil co-treated with procymidone co-treated with iprodione co-treated with cyhalothrin] results in increased phosphorylation of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of H2AX protein |
CTD |
PMID:22389207 PMID:34503147 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hes6 |
hairy and enhancer of split 6 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of HES6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:91,339,204...91,342,901
Ensembl chr 1:91,339,205...91,341,760
|
|
G |
Hnf4a |
hepatic nuclear factor 4, alpha |
decreases expression |
ISO |
procymidone results in decreased expression of HNF4A mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830
|
|
G |
Hoxa4 |
homeobox A4 |
decreases expression |
ISO |
procymidone results in decreased expression of HOXA4 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 6:52,166,662...52,168,683
Ensembl chr 6:52,166,651...52,168,733
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
decreases expression |
EXP |
procymidone results in decreased expression of HSD17B1 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr11:100,968,792...100,972,014
Ensembl chr11:100,969,237...100,971,353
|
|
G |
Hsp90b1 |
heat shock protein 90, beta (Grp94), member 1 |
decreases expression |
ISO |
procymidone results in decreased expression of HSP90B1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr10:86,526,705...86,541,308
Ensembl chr10:86,526,073...86,541,373
|
|
G |
Hspa5 |
heat shock protein 5 |
decreases expression increases expression |
ISO EXP |
procymidone results in decreased expression of HSPA5 mRNA procymidone results in increased expression of HSPA5 mRNA; procymidone results in increased expression of HSPA5 protein |
CTD |
PMID:15686871 PMID:35913088 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Htt |
huntingtin |
decreases expression |
ISO |
procymidone results in decreased expression of HTT mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:34,919,084...35,069,878
Ensembl chr 5:34,919,084...35,069,878
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
ISO |
procymidone results in decreased expression of HYOU1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 9:44,290,840...44,303,662
Ensembl chr 9:44,290,787...44,303,666
|
|
G |
Ifng |
interferon gamma |
affects expression |
EXP |
procymidone affects the expression of IFNG mRNA |
CTD |
PMID:36764477 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of IGF2R mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:12,901,293...12,988,593
Ensembl chr17:12,901,293...12,988,551
|
|
G |
Il17a |
interleukin 17A |
increases expression affects expression |
EXP |
procymidone results in increased expression of IL17A mRNA procymidone affects the expression of IL17A protein |
CTD |
PMID:36764477 |
|
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il1b |
interleukin 1 beta |
affects expression |
EXP |
procymidone affects the expression of IL1B mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1rapl1 |
interleukin 1 receptor accessory protein-like 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of IL1RAPL1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr X:85,784,543...87,159,554
Ensembl chr X:85,784,476...87,159,251
|
|
G |
Il22b |
interleukin 22B |
affects expression increases expression |
EXP |
procymidone affects the expression of IL22 protein procymidone results in increased expression of IL22 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr10:118,125,534...118,130,943
Ensembl chr10:118,125,534...118,130,943
|
|
G |
Il6 |
interleukin 6 |
affects expression |
EXP |
procymidone affects the expression of IL6 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions decreases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of INS1 protein procymidone results in decreased expression of INS1 protein |
CTD |
PMID:33246813 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Klf4 |
Kruppel-like transcription factor 4 (gut) |
increases expression multiple interactions decreases expression |
EXP |
procymidone results in increased expression of KLF4 mRNA [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of KLF4 mRNA procymidone results in decreased expression of KLF4 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
|
|
G |
Klk1b3 |
kallikrein 1-related peptidase b3 |
decreases expression |
ISO |
procymidone results in decreased expression of KLK1B3 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 7:43,847,615...43,851,775
Ensembl chr 7:43,847,615...43,851,776
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
procymidone results in increased expression of KRT18 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr15:101,936,651...101,940,461
Ensembl chr15:101,936,615...101,940,462
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
EXP |
procymidone results in decreased expression of LCN2 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Lhb |
luteinizing hormone beta |
increases expression multiple interactions |
ISO |
procymidone results in increased expression of LHB protein [vinclozolin co-treated with procymidone] results in increased expression of LHB protein |
CTD |
PMID:12563111 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Lhx5 |
LIM homeobox protein 5 |
decreases expression |
ISO |
procymidone results in decreased expression of LHX5 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:120,569,951...120,579,522
Ensembl chr 5:120,569,764...120,579,288
|
|
G |
Lrrc7 |
leucine rich repeat containing 7 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of LRRC7 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:157,772,823...158,268,254
Ensembl chr 3:157,788,528...158,267,858 Ensembl chr 3:157,788,528...158,267,858
|
|
G |
Lum |
lumican |
decreases expression |
ISO |
procymidone results in decreased expression of LUM mRNA |
CTD |
PMID:15686871 |
|
NCBI chr10:97,401,363...97,408,565
Ensembl chr10:97,400,990...97,408,565
|
|
G |
Lyz1 |
lysozyme 1 |
increases expression multiple interactions affects expression |
EXP |
procymidone results in increased expression of LYZ1 mRNA [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of LYZ1 mRNA procymidone affects the expression of LYZ1 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr10:117,123,700...117,128,773
Ensembl chr10:117,123,702...117,128,773
|
|
G |
Magi2 |
membrane associated guanylate kinase, WW and PDZ domain containing 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of MAGI2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 5:19,431,787...20,909,790
Ensembl chr 5:19,432,034...20,909,790
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases expression |
EXP |
procymidone results in increased expression of MAP3K5 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr10:19,809,847...20,018,496
Ensembl chr10:19,810,218...20,018,499
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
increases expression |
ISO |
procymidone results in increased expression of MAPK1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk10 |
mitogen-activated protein kinase 10 |
increases expression |
EXP |
procymidone results in increased expression of MAPK10 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr 5:103,056,413...103,359,200
Ensembl chr 5:103,055,814...103,359,200
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
EXP |
procymidone results in increased expression of MAPK8 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases expression |
EXP |
procymidone results in increased expression of MAPK9 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
procymidone results in decreased expression of MBP mRNA |
CTD |
PMID:15686871 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mdga2 |
MAM domain containing glycosylphosphatidylinositol anchor 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of MDGA2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr12:66,512,832...67,269,323
Ensembl chr12:66,512,834...67,269,323
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
decreases expression |
ISO |
procymidone results in decreased expression of MDM2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
decreases expression |
ISO |
procymidone results in decreased expression of ME1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006
|
|
G |
Mep1b |
meprin 1 beta |
increases expression multiple interactions affects expression |
EXP |
procymidone results in increased expression of MEP1B mRNA [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of MEP1B mRNA procymidone affects the expression of MEP1B mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr18:21,205,401...21,233,256
Ensembl chr18:21,194,980...21,233,256
|
|
G |
Mgp |
matrix Gla protein |
increases expression |
ISO |
procymidone results in increased expression of MGP mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 6:136,849,433...136,852,821
Ensembl chr 6:136,849,433...136,852,821
|
|
G |
Mir212 |
microRNA 212 |
increases expression |
EXP |
procymidone results in increased expression of MIR212 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr11:75,064,214...75,064,304
Ensembl chr11:75,064,214...75,064,304
|
|
G |
Mlxip |
MLX interacting protein |
multiple interactions |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in increased expression of MLXIP mRNA |
CTD |
PMID:33246813 |
|
NCBI chr 5:123,532,438...123,595,998
Ensembl chr 5:123,532,861...123,595,995
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
affects expression |
EXP |
procymidone affects the expression of MMP7 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 9:7,692,095...7,699,587
Ensembl chr 9:7,692,091...7,699,586
|
|
G |
Msmb |
beta-microseminoprotein |
decreases expression |
ISO |
procymidone results in decreased expression of MSMB mRNA |
CTD |
PMID:33932781 |
|
NCBI chr14:31,863,980...31,880,284
Ensembl chr14:31,863,980...31,880,327
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of MTTP mRNA procymidone results in decreased expression of MTTP mRNA procymidone results in increased expression of MTTP mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Muc1 |
mucin 1, transmembrane |
affects expression |
EXP |
procymidone affects the expression of MUC1 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
|
|
G |
Muc17 |
mucin 17, cell surface associated |
multiple interactions decreases expression increases expression |
EXP |
[tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of MUC17 mRNA procymidone results in decreased expression of MUC17 mRNA procymidone results in increased expression of MUC17 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 5:137,163,772...137,202,809
Ensembl chr 5:137,163,770...137,202,830
|
|
G |
Muc2 |
mucin 2 |
multiple interactions decreases expression |
EXP |
[tetrachloroisophthalonitrile co-treated with procymidone] results in decreased expression of MUC2 protein procymidone results in decreased expression of MUC2 mRNA; procymidone results in decreased expression of MUC2 protein |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 7:141,276,583...141,308,428
Ensembl chr 7:141,276,583...141,308,430
|
|
G |
Nat2 |
N-acetyltransferase 2 (arylamine N-acetyltransferase) |
increases expression |
ISO |
procymidone results in increased expression of NAT2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 8:67,947,527...67,955,296
Ensembl chr 8:67,947,510...67,955,236
|
|
G |
Ncan |
neurocan |
increases expression |
ISO |
procymidone results in increased expression of NCAN mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 8:70,545,735...70,573,494
Ensembl chr 8:70,545,735...70,573,523
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NF1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:79,223,541...79,472,435
Ensembl chr11:79,230,519...79,472,438
|
|
G |
Nfix |
nuclear factor I/X |
increases expression |
ISO |
procymidone results in increased expression of NFIX mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 8:85,431,341...85,527,086
Ensembl chr 8:85,426,505...85,526,973
|
|
G |
Ngf |
nerve growth factor |
decreases expression |
ISO |
procymidone results in decreased expression of NGF mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nlgn1 |
neuroligin 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:25,475,972...26,387,504
Ensembl chr 3:25,480,379...26,386,609
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
decreases expression |
ISO |
procymidone results in decreased expression of NOS3 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Notch2 |
notch 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of NOTCH2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:97,920,854...98,057,683
Ensembl chr 3:97,920,843...98,057,677
|
|
G |
Notch3 |
notch 3 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NOTCH3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:32,339,794...32,385,869
Ensembl chr17:32,339,794...32,385,826
|
|
G |
Notch4 |
notch 4 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NOTCH4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:34,783,257...34,807,517
Ensembl chr17:34,783,242...34,807,477
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases expression |
EXP |
procymidone results in increased expression of NR1H4 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO EXP |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased activity of NR1I2 protein; procymidone binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:21115097 PMID:25028461 PMID:33049310 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr2f6 |
nuclear receptor subfamily 2, group F, member 6 |
increases expression |
ISO |
procymidone results in increased expression of NR2F6 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 8:71,826,762...71,834,593
Ensembl chr 8:71,826,767...71,834,604
|
|
G |
Nrcam |
neuronal cell adhesion molecule |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRCAM mRNA |
CTD |
PMID:25607892 |
|
NCBI chr12:44,375,568...44,651,977
Ensembl chr12:44,375,668...44,648,747
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NRG1 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRG1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
|
|
G |
Nrp2 |
neuropilin 2 |
decreases expression |
ISO |
procymidone results in decreased expression of NRP2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 1:62,742,476...62,857,851
Ensembl chr 1:62,742,444...62,857,854
|
|
G |
Nrxn1 |
neurexin I |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRXN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:90,341,072...91,400,587
Ensembl chr17:90,341,059...91,400,499
|
|
G |
Nrxn2 |
neurexin II |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr19:6,468,786...6,583,247
Ensembl chr19:6,468,761...6,594,199
|
|
G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NTRK2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
|
|
G |
Ocel1 |
occludin/ELL domain containing 1 |
decreases expression |
EXP |
procymidone results in decreased expression of OCEL1 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 8:71,823,942...71,826,333
Ensembl chr 8:71,823,942...71,832,005
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
decreases expression multiple interactions |
ISO |
procymidone results in decreased expression of ODC1 mRNA [vinclozolin co-treated with procymidone co-treated with Flutamide] results in decreased expression of ODC1 mRNA |
CTD |
PMID:17420220 |
|
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
G |
P4hb |
prolyl 4-hydroxylase, beta polypeptide |
decreases expression |
ISO |
procymidone results in decreased expression of P4HB mRNA |
CTD |
PMID:15686871 |
|
NCBI chr11:120,451,124...120,464,079
Ensembl chr11:120,451,124...120,464,079
|
|
G |
Pdcd2 |
programmed cell death 2 |
increases expression |
ISO |
procymidone results in increased expression of PDCD2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr17:15,739,472...15,747,560
Ensembl chr17:15,739,470...15,747,563
|
|
G |
Pdia3 |
protein disulfide isomerase associated 3 |
decreases expression |
ISO |
procymidone results in decreased expression of PDIA3 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168
|
|
G |
Pdia4 |
protein disulfide isomerase associated 4 |
decreases expression |
ISO |
procymidone results in decreased expression of PDIA4 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 6:47,773,075...47,790,446
Ensembl chr 6:47,773,075...47,790,364
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PGR mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pgrmc1 |
progesterone receptor membrane component 1 |
decreases expression |
ISO |
procymidone results in decreased expression of PGRMC1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr X:35,861,846...35,869,732
Ensembl chr X:35,861,859...35,869,732
|
|
G |
Pip |
prolactin induced protein |
decreases expression |
ISO |
procymidone results in decreased expression of PIP mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 6:41,824,483...41,828,999
Ensembl chr 6:41,824,469...41,828,999
|
|
G |
Pklr |
pyruvate kinase liver and red blood cell |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of PKLR mRNA procymidone results in decreased expression of PKLR mRNA procymidone results in increased expression of PKLR mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
multiple interactions increases expression affects expression |
EXP |
[tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of PLA2G4A mRNA procymidone results in increased expression of PLA2G4A mRNA procymidone affects the expression of PLA2G4A mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Plat |
plasminogen activator, tissue |
decreases expression |
ISO |
procymidone results in decreased expression of PLAT mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression increases expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of PPARA mRNA procymidone results in decreased expression of PPARA mRNA procymidone results in increased expression of PPARA mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases expression affects expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of PPARG mRNA; procymidone binds to and results in increased activity of PPARG protein procymidone results in decreased expression of PPARG mRNA procymidone affects the expression of PPARG mRNA |
CTD |
PMID:33049310 PMID:33246813 PMID:36764477 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Prdx1 |
peroxiredoxin 1 |
decreases expression |
ISO |
procymidone results in decreased expression of PRDX1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
|
|
G |
Prkar1a |
protein kinase, cAMP dependent regulatory, type I, alpha |
decreases expression |
ISO |
procymidone results in decreased expression of PRKAR1A mRNA |
CTD |
PMID:15686871 |
|
NCBI chr11:109,539,849...109,560,489
Ensembl chr11:109,540,231...109,560,482
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
procymidone results in increased expression of PTEN mRNA |
CTD |
PMID:15686871 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
increases expression |
ISO |
procymidone results in increased expression of RBL2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 8:91,796,685...91,850,472
Ensembl chr 8:91,796,685...91,850,472
|
|
G |
Reg3g |
regenerating islet-derived 3 gamma |
affects expression |
EXP |
procymidone affects the expression of REG3G mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 6:78,443,252...78,445,857
Ensembl chr 6:78,443,252...78,445,855
|
|
G |
Reln |
reelin |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of RELN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 5:22,089,452...22,549,703
Ensembl chr 5:22,089,452...22,549,700
|
|
G |
Retnlb |
resistin like beta |
affects expression |
EXP |
procymidone affects the expression of RETNLB mRNA |
CTD |
PMID:36764477 |
|
NCBI chr16:48,637,219...48,639,255
Ensembl chr16:48,637,219...48,639,255
|
|
G |
Robo1 |
roundabout guidance receptor 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ROBO1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:71,824,406...72,844,379
Ensembl chr16:72,105,194...72,842,983
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of RXRA mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
decreases expression multiple interactions increases expression |
EXP |
procymidone results in decreased expression of SCD1 mRNA [procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of SCD1 mRNA procymidone results in increased expression of SCD1 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Scgb2a2 |
secretoglobin, family 2A, member 2 |
decreases expression |
ISO |
procymidone results in decreased expression of SCGB2A2 mRNA |
CTD |
PMID:15590119 |
|
NCBI chr19:9,824,922...9,829,564
Ensembl chr19:9,824,926...9,830,172
|
|
G |
Shank2 |
SH3 and multiple ankyrin repeat domains 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:143,531,819...143,979,780
Ensembl chr 7:143,555,665...143,978,231
|
|
G |
Slc10a2 |
solute carrier family 10, member 2 |
increases expression |
EXP |
procymidone results in increased expression of SLC10A2 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 8:5,133,219...5,155,287
Ensembl chr 8:5,133,219...5,155,351
|
|
G |
Slc12a2 |
solute carrier family 12, member 2 |
multiple interactions increases expression affects expression |
EXP |
[tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of SLC12A2 mRNA procymidone results in increased expression of SLC12A2 mRNA procymidone affects the expression of SLC12A2 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr18:58,011,505...58,079,893
Ensembl chr18:58,011,750...58,079,893
|
|
G |
Slc1a2 |
solute carrier family 1 (glial high affinity glutamate transporter), member 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:102,488,584...102,621,129
Ensembl chr 2:102,489,004...102,621,129
|
|
G |
Slc1a6 |
solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SLC1A6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:78,615,923...78,650,659
Ensembl chr10:78,616,330...78,650,599
|
|
G |
Slc26a3 |
solute carrier family 26, member 3 |
multiple interactions affects expression |
EXP |
[tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of SLC26A3 mRNA procymidone affects the expression of SLC26A3 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr12:31,483,141...31,523,921
Ensembl chr12:31,440,870...31,523,916
|
|
G |
Slc26a6 |
solute carrier family 26, member 6 |
affects expression |
EXP |
procymidone affects the expression of SLC26A6 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 9:108,731,239...108,742,117
Ensembl chr 9:108,730,482...108,742,117
|
|
G |
Slc27a2 |
solute carrier family 27 (fatty acid transporter), member 2 |
multiple interactions decreases expression affects expression |
EXP |
[procymidone co-treated with tetrachloroisophthalonitrile] results in decreased expression of SLC27A2 mRNA procymidone results in decreased expression of SLC27A2 mRNA procymidone affects the expression of SLC27A2 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 2:126,394,944...126,430,163
Ensembl chr 2:126,394,327...126,430,163
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
decreases expression affects expression |
EXP |
procymidone results in decreased expression of SLC2A2 mRNA procymidone affects the expression of SLC2A2 mRNA |
CTD |
PMID:33246813 PMID:36764477 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc51a |
solute carrier family 51, alpha subunit |
affects expression |
EXP |
procymidone affects the expression of SLC51A mRNA |
CTD |
PMID:36764477 |
|
NCBI chr16:32,294,396...32,306,697
Ensembl chr16:32,293,322...32,306,697
|
|
G |
Slc9a2 |
solute carrier family 9 (sodium/hydrogen exchanger), member 2 |
affects expression |
EXP |
procymidone affects the expression of SLC9A2 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 1:40,720,872...40,808,045
Ensembl chr 1:40,719,734...40,808,433
|
|
G |
Slc9a3 |
solute carrier family 9 (sodium/hydrogen exchanger), member 3 |
increases expression multiple interactions |
EXP |
procymidone results in increased expression of SLC9A3 mRNA [tetrachloroisophthalonitrile co-treated with procymidone] results in increased expression of SLC9A3 mRNA |
CTD |
PMID:33246813 |
|
NCBI chr13:74,234,374...74,317,561
Ensembl chr13:74,269,576...74,317,561
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases expression |
ISO |
procymidone results in decreased expression of SLCO1A4 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slit1 |
slit guidance ligand 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SLIT1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr19:41,586,263...41,735,714
Ensembl chr19:41,588,696...41,732,104
|
|
G |
Smad2 |
SMAD family member 2 |
decreases expression |
ISO |
procymidone results in decreased expression of SMAD2 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034
|
|
G |
Sptbn2 |
spectrin beta, non-erythrocytic 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SPTBN2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr19:4,761,236...4,804,006
Ensembl chr19:4,761,195...4,802,388
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
procymidone results in decreased expression of STAR mRNA |
CTD |
PMID:35913088 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Stmn2 |
stathmin-like 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of STMN2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:8,574,587...8,626,664
Ensembl chr 3:8,574,420...8,626,666
|
|
G |
Sts |
steroid sulfatase |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of STS mRNA |
CTD |
PMID:25607892 |
|
NCBI chr X:168,856,332...169,015,037
Ensembl chr X:168,909,030...169,014,924
|
|
G |
Stxbp1 |
syntaxin binding protein 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of STXBP1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:32,677,619...32,737,249
Ensembl chr 2:32,677,614...32,737,257
|
|
G |
Sult1b1 |
sulfotransferase family 1B, member 1 |
increases expression |
ISO |
procymidone results in increased expression of SULT1B1 mRNA |
CTD |
PMID:15686871 |
|
NCBI chr 5:87,661,186...87,686,054
Ensembl chr 5:87,661,198...87,686,054
|
|
G |
Syngap1 |
synaptic Ras GTPase activating protein 1 homolog (rat) |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of SYNGAP1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:27,160,186...27,191,408
Ensembl chr17:27,160,227...27,191,408
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of SYP mRNA |
CTD |
PMID:25607892 |
|
NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of TGFB1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Thrb |
thyroid hormone receptor beta |
affects binding multiple interactions |
ISO |
procymidone binds to THRB protein procymidone binds to and results in increased activity of THRB protein |
CTD |
PMID:28973306 PMID:33049310 |
|
NCBI chr14:4,429,599...4,810,538
Ensembl chr14:4,431,611...4,809,435
|
|
G |
Tjp1 |
tight junction protein 1 |
decreases expression |
EXP |
procymidone results in decreased expression of TJP1 mRNA |
CTD |
PMID:36764477 |
|
NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
procymidone results in increased expression of TNF mRNA |
CTD |
PMID:36764477 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Traf2 |
TNF receptor-associated factor 2 |
increases expression |
EXP |
procymidone results in increased expression of TRAF2 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr 2:25,407,994...25,436,952
Ensembl chr 2:25,407,994...25,436,952
|
|
G |
Trp53bp1 |
transformation related protein 53 binding protein 1 |
multiple interactions |
ISO |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] affects the expression of TP53BP1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] affects the expression of TP53BP1 protein |
CTD |
PMID:34503147 |
|
NCBI chr 2:121,025,316...121,126,830
Ensembl chr 2:121,023,762...121,101,888
|
|
G |
Tsc2 |
TSC complex subunit 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of TSC2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:24,814,788...24,851,607
Ensembl chr17:24,814,790...24,851,604
|
|
G |
Tspo |
translocator protein |
decreases expression |
ISO |
procymidone results in decreased expression of TSPO mRNA |
CTD |
PMID:15686871 |
|
NCBI chr15:83,447,774...83,458,404
Ensembl chr15:83,447,793...83,458,404
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
ISO |
procymidone results in increased expression of TUBA1A mRNA |
CTD |
PMID:15686871 |
|
NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584
|
|
G |
Unc5b |
unc-5 netrin receptor B |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of UNC5B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:60,598,373...60,667,360
Ensembl chr10:60,598,372...60,667,360
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
EXP |
procymidone results in increased expression of XBP1 mRNA |
CTD |
PMID:35913088 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
G |
Zc3h4 |
zinc finger CCCH-type containing 4 |
decreases expression |
EXP |
procymidone results in decreased expression of ZC3H4 mRNA; procymidone results in decreased expression of ZC3H4 mRNA alternative form |
CTD |
PMID:35913088 |
|
NCBI chr 7:16,132,549...16,171,621
Ensembl chr 7:16,134,835...16,171,621
|
|